Skip to main content
Gregory Riely, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

GregoryJRielyMDPhD

Oncology New York, NY

Thoracic Cancer

Attending Physician Thoracic Oncology Service, Department of Medicine, Memorial Hospital Member Memorial Sloan Kettering Cancer Center

Overview of Dr. Riely

Dr. Gregory Riely, MD is an oncologist in New York, New York. He is currently licensed to practice medicine in New York and North Carolina. He is affiliated with Memorial Sloan-Kettering Cancer Center.

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellowship, Hematology/Oncology, 2003 - 2006
  • New York Presbyterian Hospital - Cornell Campus
    New York Presbyterian Hospital - Cornell CampusResidency, Internal Medicine, 2001 - 2003
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 2001

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2020 - Present
  • NY State Medical License
    NY State Medical License 2003 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers  
    Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
  • PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers  
    G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology
  • YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics  
    Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

  • Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. 
    2019 ASCO Annual Meeting - 6/1/2019
  • American Society for Radiation Oncology(ASTRO): 20th Chicago Multidisciplinary Symposium inThoracic Oncology 
    American Society for Radiation Oncology, Chicago, Illinois - 9/6/2012
  • Treating Stage I to III Non-Small-Cell Lung Cancer With Limited Evidence 
    2013 International Conference, Philadelphia, Pennsylvania, USA
  • Join now to see all

Press Mentions

  • ASCO 2019: Tepotinib and Capmatinib Fight over a New Lung Cancer Niche
    ASCO 2019: Tepotinib and Capmatinib Fight over a New Lung Cancer NicheJune 4th, 2019
  • Two New Targeted Therapies Appear Encouraging for Difficult Drivers in NSCLC
    Two New Targeted Therapies Appear Encouraging for Difficult Drivers in NSCLCJune 4th, 2019
  • Thymus Cancer Market to Grow Exponential with Astellas Pharma | Astrazeneca | Bristol-Myers Squibb | Takeda Pharmaceutical Company, Etc. – Asserts MRFR Unleashing Industry Forecast to 2024
    Thymus Cancer Market to Grow Exponential with Astellas Pharma | Astrazeneca | Bristol-Myers Squibb | Takeda Pharmaceutical Company, Etc. – Asserts MRFR Unleashing Industry Forecast to 2024May 8th, 2018
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Kaiser Permanente
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment